Article
Selumetinib plus dacarbazine versus placebo plus dacarbazine as first-line treatment for BRAF-mutant metastatic melanoma: a phase 2 double-blind randomised study.
The Lancet. Oncology - 1 Jul 2013
Robert Caroline, Dummer Reinhard, Gutzmer Ralf, Lorigan Paul, Kim Kevin B, Nyakas Marta, Arance Ana, Liszkay Gabriella, Schadendorf Dirk, Cantarini Mireille, Spencer Stuart, Middleton Mark R
Abstract excerpt
BACKGROUND: Patients with metastatic melanoma, 50% of whose tumours harbour a BRAF mutation, have a poor prognosis. Selumetinib, a MEK1/2 inhibitor, has shown antitumour activity in patients with BRAF-mutant melanoma and in preclinical models when combined with chemotherapy. This study was designed to look for a signal of improved efficacy by comparing the combination of selumetinib and dacarbazine with...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.